• Profile
Close

Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience

The Breast Journal Jan 10, 2018

Martin-Romano P, et al. - The efficacy, toxicity, and long-term outcome of the combination of pegylated liposomal doxorubicin (PLD) plus gemcitabine (GEM) in heavily pretreated metastatic breast cancer (MBC) patients were assessed. The PLD-GEM combination resulted in remarkable long-term outcomes with an acceptable toxicity profile in these patients.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay